A Study of Fluconazole in the Treatment of Fungal Infections of the Throat in Patients With Weakened Immune Systems
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
To determine the safety, toleration, and efficacy of fluconazole oral suspension in the treatment of esophageal candidiasis in immunocompromised patients, including those with AIDS.
Condition or disease
Candidiasis, EsophagealHIV Infections
Patients receive fluconazole oral suspension for a minimum of 3 weeks and maximum of 8 weeks. Patients are evaluated weekly, and treatment continues for 2 weeks after resolution of symptoms. Endoscopic exams and possibly biopsies are performed at baseline and at the end of treatment. Patients undergo follow-up at 2 weeks post-treatment.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
13 Years to 70 Years (Child, Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients must have:
AIDS or other immunocompromising condition.
Life expectancy of at least 2 months.
Patients with the following symptoms or conditions are excluded:
Evidence of non-candidal systemic fungal infection.
Abnormalities that may preclude esophagoscopy or endoscopy.
Unable to tolerate fluconazole.
Unable to give informed consent.
Enrollment in other experimental trials of approved or non-approved drugs or systemic compounds (unless approved by the Pfizer Clinical Monitor).
Other condition that would make patient unsuitable for enrollment.
Concomitant oral or topical antifungal agent.
Other experimental medications.
Patients with the following prior condition are excluded:
History of allergy to imidazoles or azoles.
Any oral or topical antifungal therapy within the past 3 days. Active use of illicit or illegal drugs.